Gefitinib is used for: Non-small Cell Lung Cancer.
Recorded in the NepalDoc medicine catalog for Gefitinib.
Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
From the U.S. FDA-approved label for Gefitinib. Full label: DailyMed.
Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.
From the U.S. FDA-approved label for Gefitinib. Full label: DailyMed.
Recommended dose is 250 mg orally, once daily with or without food. 2.1 Patient Selection Select patients for the first-line treatment of metastatic NSCLC with gefitinib tablets based on the presence of EGFR exon 19 deletions or exon 21 L858R mutations in their tumor or plasma specimens. If these mutations are not detected in a plasma specimen, test tumor tissue if feasible.
Directions from the U.S. FDA-approved label for Gefitinib — your doctor or pharmacist may advise differently.
Interstitial lung disease (ILD): ILD occurred in patients taking gefitinib tablets. Withhold gefitinib tablets for worsening of respiratory symptoms. Discontinue gefitinib tablets if ILD is confirmed.,Hepatotoxicity: Obtain periodic liver function testing. Withhold gefitinib tablets for Grade 2 or higher for ALT and/or AST elevations.
Warnings and precautions excerpt from the U.S. FDA-approved label for Gefitinib — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse drug reactions are discussed in more detail in other sections of the labeling: Interstitial Lung Disease, Hepatotoxicity, Gastrointestinal Perforation, Severe or Persistent Diarrhea, Ocular Disorders including Keratitis, Bullous and Exfoliative Skin Disorders The most commonly reported adverse drug reactions (ADRs), reported in more than 20% of the patients and greater than placebo were skin reactions…
Excerpt from the U.S. FDA-approved label for Gefitinib — not a complete list. Talk to a pharmacist or doctor about side effects.
5 brands · 4 makers in the NepalDoc catalog — see the full Gefitinib guide →
Store at controlled room temperature 20°C-25°C (68°F-77°F).
Storage information from the U.S. FDA-approved label for Gefitinib.
What is GEFTINIB?
GEFTINIB 250MG Tablet is a Gefitinib medicine made by DABUR INDIA LTD. It comes as 250MG Tablet.
What is GEFTINIB used for?
Gefitinib is used for Non-small Cell Lung Cancer.
What is the generic name of GEFTINIB?
The generic name of GEFTINIB is Gefitinib.
Which brands of Gefitinib are available in Nepal?
5 brands of Gefitinib are listed in the NepalDoc catalog, from 4 makers — including Geftilon 250mg Tablet, Geftinat 250mg Tablet, GENTILON 250MG Tablet, Kabigef 250mg Tablet.
What are the side effects of Gefitinib?
The following adverse drug reactions are discussed in more detail in other sections of the labeling: Interstitial Lung Disease, Hepatotoxicity, Gastrointestinal Perforation, Severe or Persistent Diarrhea, Ocular Disorders including Keratitis, Bullous and Exfoliative Skin Disorders The most commonly reported adverse drug reactions (ADRs), reported in more than 20% of the patients and greater than placebo were skin reactions…
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
